First Published: 25th November 2025
Cumulus Neuroscience today announced the acceptance of an abstract titled, "Validating a Multi-Domain Digital Endpoint Platform (NeuLogiq) for Decentralized Alzheimer’s Trials: Results from the CNS-101 Study" by the Scientific Program Committee for the 18th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference which will be held December 1-4, 2025, in San Diego, California.
In addition to the poster presentation, Cumulus Co-Founder and CSO Brian Murphy, PhD will give an oral presentation during the CTAD 2025 Biotech Showcase.
"The acceptance of our poster and oral presentation at CTAD reflect the conviction in the community that we need better tools, like NeuLogiq, to screen and measure efficacy in new treatments." said Brian Murphy, PhD, Co-Founder and CSO of Cumulus Neuroscience. "CTAD is the premier global forum for Alzheimer's clinical research, and we look forward to sharing our latest data from the CNS-101 study at this pivotal conference."
The details of the showcase and poster presentation are as follows:
Showcase Presentation- Title: Remote Digital Biomarkers for Trial Efficiency
- Date & Time: Tuesday, December 2: 3:50 PM – 4:20 PM
- Session: Digital and Neurotechnology-Based Biomarkers and Therapeutics. Focus: novel neurotech and at-home stimulation tools
- Title: Validating a Multi-Domain Digital Endpoint Platform (NeuLogiq) for Decentralized Alzheimer’s Trials: Results from the CNS-101 Study
- Date & Time: Thursday, December 4: 7:15 AM – 5:00 PM
- Session: Digital Health/E-Trials
- Poster Number: P394
Cumulus continues to advance NeuLogiq, an integrated AI-based, multi-domain digital biomarker platform, providing biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions. To learn more, visit www.cumulusneuro.com.